The canonical profile remains the primary reading view. Read the canonical profile.
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which names survodutide among unapproved drugs sold with false research-use labels. 257
What this version reported
Published randomized trials, including the Phase 3 SYNCHRONIZE-1 trial, report weight loss and liver-fat reductions. A completed cardiovascular safety trial has no results in the cited sources. FDA has warned companies selling unapproved survodutide with false research-use labels.↗↗↗↗
Trial records: NCT05202353
Reader guide in this version
Key takeaway
Survodutide is an experimental peptide from Boehringer Ingelheim that activates the receptors for two hormones, glucagon and GLP-1.1,3 It is not FDA-approved, and FDA has warned companies that sold unapproved drugs containing survodutide falsely labeled as being for research purposes.2 Published randomized trials report weight loss in obesity, including the 725-person Phase 3 SYNCHRONIZE-1 trial, and improvements in liver measures in people with fatty liver disease.4,5,6
At a glance
- What it is
- An investigational glucagon receptor and GLP-1 receptor dual agonist from Boehringer Ingelheim, also known as BI 456906.1,3
- FDA status
- Not FDA-approved. FDA lists survodutide among unapproved drugs it has warned companies for selling with false research-use labels.2
- Human evidence
- Randomized trials reported in journals: two Phase 2 trials and two Phase 3 trials. A completed cardiovascular safety trial and other Phase 3 trials are registered.3,4,5,6,7
- Evidence strength
- Large randomized human trials
What is survodutide?
Survodutide, also known as BI 456906, is an experimental peptide being developed by Boehringer Ingelheim, which ClinicalTrials.gov lists as the sponsor of the trial record cited on this profile.1
The Phase 2 obesity trial report describes it as a glucagon receptor and GLP-1 receptor dual agonist.3
How is survodutide thought to work?
Survodutide is designed to act on two hormone receptors at once: the GLP-1 receptor and the glucagon receptor.3
A Boehringer Ingelheim trial registered on ClinicalTrials.gov compares survodutide with semaglutide on glucagon receptor activity in the liver.1
The sources reviewed here do not establish how much each receptor contributes to the effects reported in trials.3,5
What do human studies show?
In SYNCHRONIZE-1, a Phase 3 trial of 725 adults with obesity, or overweight with a related condition, and no diabetes, average weight change at 76 weeks was −12.2% and −13.0% in the two survodutide groups, compared with −5.4% with placebo.5
Gastrointestinal events occurred in 80.9% and 89.7% of the survodutide groups and 47.9% of the placebo group in that trial, and no deaths were reported.5
In the earlier Phase 2 obesity trial of 386 adults, average weight change over 46 weeks ranged from −6.2% to −14.9% across the planned survodutide groups, compared with −2.8% with placebo. About 60% of participants completed the treatment period.3
In a Phase 2 trial of 293 adults with biopsy-confirmed MASH and liver fibrosis, improvement in MASH without worsening fibrosis was reported in 43% to 62% across the survodutide groups and 14% with placebo after 48 weeks.4
In SYNCHRONIZE-MASLD, 68.5% of the survodutide group and 28.6% of the placebo group reached at least a 30% reduction in liver fat measured by MRI at 48 weeks. MRI liver fat is not the same as fewer liver-related illnesses or deaths.6
What the evidence base contains
- Large randomized human trial SYNCHRONIZE-1, a 76-week blinded, randomized, placebo-controlled Phase 3 trial in 725 adults with obesity, or overweight with a related condition, that excluded diabetes, published in The New England Journal of Medicine.5
- Large randomized human trial A 46-week randomized, double-blind, placebo-controlled Phase 2 trial that treated 386 adults with overweight or obesity without diabetes, published in The Lancet Diabetes & Endocrinology.3
- Controlled human trial A 48-week randomized, placebo-controlled Phase 2 trial that treated 293 adults with biopsy-confirmed MASH and liver fibrosis, published in The New England Journal of Medicine.4
- Controlled human trial SYNCHRONIZE-MASLD, a 48-week blinded, randomized, placebo-controlled Phase 3 trial in 216 treated adults with obesity and fatty liver disease, published in Nature Medicine.6
- Registered trial without results SYNCHRONIZE-CVOT (NCT06077864), a Phase 3 cardiovascular safety trial in people with overweight or obesity, listed as completed in its August 11, 2026 registry record. Its results are not part of the sources cited here.7
Evidence-strength label: Large randomized human trials. How this label is assigned
Is survodutide FDA-approved?
No. Survodutide remains in clinical trials. None of the sources reviewed here reports an approval of survodutide in any country.1,2,9
FDA’s page on unapproved GLP-1 drugs, current as of October 1, 2026, says FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled as being for research purposes or not for human consumption.2
FDA says these products have been sold directly to consumers for human use, and it urges consumers to avoid them because they are of unknown quality.2
Boehringer Ingelheim has registered further Phase 3 trials, including a MASH trial that was recruiting and a type 2 diabetes trial that was not yet recruiting in their August 10, 2026 registry records.8,9
Timeline
- Results of Phase 2 trials in obesity and in MASH with fibrosis are published.3,4
- Results of the Phase 3 trials SYNCHRONIZE-1 and SYNCHRONIZE-MASLD are published.5,6
- FDA’s page on unapproved GLP-1 drugs, which names survodutide among drugs sold with false research-use labels, is updated, as shown by its content-current date.2
What is still unknown?
Whether survodutide is safe for the heart over the long term: the SYNCHRONIZE-CVOT trial is listed as completed, but its results are not part of the sources cited here.7
Whether its liver-fat and liver-tissue changes lead to fewer liver-related illnesses or deaths, which the trials reviewed here were not designed to show.4,6
Whether weight loss is maintained after treatment stops, and how often less common harms occur over longer periods.3,5
What is in survodutide products marketed outside clinical trials, which FDA describes as unapproved and of unknown quality.2
Sources for this version
- 1BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver · record history version 50 · last update posted 2026-07-22 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 2FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (2024) · PMID 38330987 ↗
The Lancet Diabetes & Endocrinology · Official source · Source checked November 14, 2026
- 4A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024) · PMID 38847460 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 5Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1, 2026) · PMID 42253238 ↗
The New England Journal of Medicine · Official source · Source checked November 14, 2026
- 6Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (2026) · PMID 42252333 ↗
Nature Medicine · Official source · Source checked November 14, 2026
- 7ClinicalTrials.gov record NCT06077864 · retained source version 2026-08-11:60e24ca2b3858aa7bfd06f0e1cac79051207229d8181cdbe15a0399bddf60984 ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026
- 8ClinicalTrials.gov record NCT06632444 · retained source version 2026-08-10:1ea3a43e551b6ef84f40e37bc415c00395c246a224788f11cf329d28dbe0b087 ↗
ClinicalTrials.gov · Official source · Source checked August 13, 2026
- 9ClinicalTrials.gov record NCT07754461 · retained source version 2026-08-10:d71d6065261ae9f1c83fbc9694b2dc6cef63964c1377569876a214c0a75eb88e ↗
ClinicalTrials.gov · Official source · Source checked August 14, 2026